From CEO to Scientist: Altieri's Move to Jefferson Heralds New Cancer Era

PHILADELPHIA, PA – May 19, 2026 – In a move that underscores the profound value of fundamental discovery, internationally renowned cancer researcher Dr. Dario C. Altieri will transition from a top executive role to join the faculty at Thomas Jefferson University's Sidney Kimmel Medical College. The appointment, effective January 1, 2027, marks the end of a transformative decade-long leadership tenure at The Wistar Institute and the beginning of a new chapter dedicated exclusively to laboratory science and mentorship at Jefferson.

Dr. Altieri will serve as Professor in the Department of Pharmacology, Physiology and Cancer Biology and the Department of Biochemistry and Molecular Biology, as well as a Special Advisor to the Director of the Sidney Kimmel Comprehensive Cancer Center. The move is being hailed by both institutions as a strategic return to the bench for one of oncology's most accomplished physician-scientists, positioning him to accelerate the search for new cancer therapies.

A Deliberate Return to the Bench

After serving as President and CEO of The Wistar Institute since 2015, Dr. Altieri is deliberately stepping away from executive leadership to immerse himself in the work that has defined his career: hands-on scientific investigation. It's a move that speaks volumes about his personal commitment and the priorities of the institutions involved.

"I look forward to dedicating myself entirely to my lifelong passion of conducting basic medical research in pursuit of lifesaving therapies," Dr. Altieri stated. "Jefferson shares a deep commitment to advancing scientific discovery and translating it into significant improvements in patient care. I am excited to join a pioneering institution where basic research, clinical excellence and medical education converge every day."

This sentiment is echoed enthusiastically by Jefferson's leadership, who see the appointment as a significant strategic acquisition. "Jefferson has long been home to world-class research, and Dr. Altieri's arrival deepens that tradition in a meaningful way," said Said Ibrahim, MD, MPH, MBA, Dean of Sidney Kimmel Medical College. "His foundational contributions to cancer biology, his record of training exceptional scientists and his commitment to translating discovery into clinical impact align perfectly with who we are and what we stand for... I could not be more proud to welcome him."

The appointment is not just a personnel change; it represents a powerful statement about the importance of basic science. By attracting a leader who chose the laboratory over the corner office, Jefferson reinforces its identity as an institution where fundamental discovery is paramount.

A Legacy of Transformative Leadership and Discovery

Dr. Altieri’s career is distinguished by groundbreaking contributions to understanding how cancer cells survive and thrive. He is most famous for his lab's discovery and characterization of survivin, an Inhibitor of Apoptosis (IAP) protein that is overproduced in nearly all human cancers. This pivotal work revealed how tumors evade programmed cell death and has since established survivin as a critical target for novel anti-cancer therapies. His more recent research has delved into mitochondrial reprogramming and tumor plasticity—the mechanisms that allow cancer cells to adapt, resist treatment, and metastasize.

His impact extends far beyond his own laboratory. During his tenure as President and CEO, The Wistar Institute experienced unprecedented growth. Under his guidance, the institute's endowment tripled to $277 million, its annual budget quadrupled to over $100 million, and its scientific footprint expanded with the establishment of two new research centers. This period of financial and scientific expansion solidified Wistar's global reputation.

Rick Horowitz, Chair of The Wistar Institute Board of Trustees, acknowledged his profound impact. "Dario has been an extraordinary leader for Wistar, instrumental in advancing the cutting-edge cancer, infectious disease and immunology research that sets The Wistar Institute apart," he said. "We are indebted to Dr. Altieri for the transformational contributions he has made."

Bolstering a Newly Crowned Comprehensive Cancer Center

Dr. Altieri joins Jefferson at a pivotal moment. In April 2024, its Sidney Kimmel Comprehensive Cancer Center (SKCCC) earned the prestigious "Comprehensive" designation from the National Cancer Institute (NCI)—the highest honor awarded by the NCI, held by only an elite group of 57 centers nationwide. This status recognizes excellence in laboratory science, clinical trials, and population-based research.

His arrival is set to amplify this momentum. As a Special Advisor to the Director, Dr. Altieri will bring decades of scientific and leadership experience to bear on SKCCC's mission. His expertise in translational medicine—bridging the gap between lab discoveries and patient treatments—is a perfect fit for a Comprehensive Cancer Center.

"It is a great honor to have Dr. Altieri join Sidney Kimmel Comprehensive Cancer Center. His contributions to cancer biology are foundational and he brings extraordinary scientific depth and leadership experience to bear on our mission," said Andrew Chapman, DO, FACP, Director of the SKCCC. "Dr. Altieri's arrival at Jefferson represents new possibilities for our research programs, our faculty and ultimately our patients."

Reshaping Philadelphia's Collaborative Science Ecosystem

The transition is more than a story about one scientist or two institutions; it has implications for Philadelphia's entire life sciences ecosystem. Rather than a competitive loss for Wistar, the move is being framed as a realignment that could foster deeper, more synergistic collaborations between two of the city's research powerhouses.

With a foot in both camps, Dr. Altieri is uniquely positioned to act as a bridge, facilitating joint projects and strengthening the pre-existing collaborative agreements between the institutions. Wistar's leadership has already signaled an optimistic outlook for the future.

"We anticipate opportunities for future collaboration with Jefferson that will strengthen the region's life science sector to drive innovation here and beyond," noted Horowitz. This spirit of cooperation suggests that Dr. Altieri's move will enhance, not diminish, the collective strength of cancer research in Philadelphia.

By returning to his first passion, Dr. Altieri is poised to not only advance his own critical research into the vulnerabilities of cancer but also to inspire a new generation of scientists and foster a more collaborative research environment across the city, all in the enduring quest for lifesaving therapies.